奥赛康(002755) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥495,669,082.18, representing a decrease of 35.64% compared to the same period last year[6]. - The net profit attributable to shareholders was -¥80,739,517.03, a decline of 162.66% year-over-year[6]. - The company reported a significant drop in operating income, which fell by 38.38% to ¥1,506,190,272.21 for the year-to-date period[11]. - Total operating revenue for the current period was ¥1,506,190,272.21, a decrease of 38.3% compared to ¥2,444,241,273.64 in the previous period[25]. - Net profit for the current period was a loss of ¥95,859,950.66, compared to a profit of ¥386,199,758.52 in the previous period[26]. - Total comprehensive income for the current period was a loss of ¥82,457,407.75, compared to a gain of ¥385,160,908.59 in the previous period[26]. - The company's diluted earnings per share were -¥0.09, reflecting a decrease of 162.66% compared to the same period last year[6]. - The basic and diluted earnings per share for the current period were both -¥0.07, compared to ¥0.42 in the previous period[26]. Cash Flow - The net cash flow from operating activities was ¥40,252,389.49, down 85.68% compared to the previous year[6]. - Cash flow from operating activities was ¥1,861,968,955.89, a decrease of 36.6% from ¥2,935,786,818.33 in the previous period[28]. - Net cash flow from operating activities was $40,252,389.49, a decrease of 85.7% compared to $281,063,579.72 in the previous period[31]. - Net cash flow from financing activities improved to $62,818,814.30 from a negative $215,688,346.33 in the previous period[31]. - The total cash and cash equivalents at the end of the period stood at $833,144,628.84, slightly down from $843,098,931.28 at the end of the previous period[31]. - Cash inflow from financing activities totaled $157,018,000.00, while cash outflow was $94,199,185.70, resulting in a net inflow[31]. - The company experienced a cash outflow of $1,379,680,361.35 related to other operating activities, down from $2,064,282,444.26 previously[31]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,582,156,515.36, a decrease of 3.83% from the end of the previous year[6]. - Total current assets as of September 30, 2022, amounted to RMB 2,331,415,792.82, a decrease from RMB 2,487,089,720.87 at the beginning of the year, representing a decline of approximately 6.3%[18]. - Total assets as of September 30, 2022, were RMB 3,582,156,515.36, down from RMB 3,724,750,010.48, indicating a decrease of about 3.8%[21]. - Total liabilities decreased to RMB 394,428,816.95 from RMB 497,243,823.11, a reduction of approximately 20.7%[21]. - The company reported a total equity of RMB 928,160,351.00, unchanged from the previous period[21]. - The equity attributable to shareholders of the parent company was ¥3,132,343,176.60, a decrease from ¥3,218,681,536.00 in the previous period[24]. Research and Development - Research and development expenses increased by 58.95% to ¥389,683,503.06, reflecting the company's commitment to biopharmaceutical and innovative drug development[11]. - Research and development expenses increased to ¥389,683,503.06, up 58.7% from ¥245,165,221.78 in the previous period[25]. - The company’s development expenditure increased to RMB 360,228,568.13 from RMB 308,836,511.73, reflecting an increase of approximately 16.6%[21]. Other Financial Metrics - The weighted average return on net assets was -1.27%, a decline of 5.34% year-over-year[6]. - The company recorded a total of ¥10,968,833.83 in non-recurring gains and losses for the reporting period[7]. - Other comprehensive income after tax for the current period was ¥13,402,542.91, compared to -¥1,038,849.93 in the previous period[26]. - The company experienced a 39.73% decrease in accounts receivable, totaling ¥298,866,959.82, primarily due to reduced sales[11]. - Accounts receivable decreased to RMB 298,866,959.82 from RMB 495,904,753.30, a reduction of approximately 39.7%[18]. - The company’s inventory as of September 30, 2022, was RMB 140,982,466.88, slightly down from RMB 141,844,960.70[18]. - The company has a total of 21,360 common shareholders, with the largest shareholder holding 34.20%[15]. - The company’s long-term equity investments increased to RMB 102,246,686.65 from RMB 101,844,628.76, a slight increase of about 0.4%[18].